Clinical Trial: Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional




Official Title: Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients

Brief Summary:

The goal of this clinical research study is to learn if it is feasible to give a beta-blocker such as Inderal (propranolol hydrochloride) with standard chemotherapy (paclitaxel and carboplatin or possibly docetaxel) to treat ovarian cancer. The safety of propranolol hydrochloride will also be studied.

Propranolol hydrochloride is designed to block certain chemicals that affect the heart. Researchers want to learn if this might also boost the immune system, allowing the chemotherapy to be more effective.

Paclitaxel is designed to block cancer cells from dividing, which may cause them to die.

Carboplatin is designed to interfere with the growth of cancer cells by stopping cell division, which may cause the cells to die.